Search
-
Ipsos Op-Ed: Trump 2.0: Populism's Ultimate Test in American Governance
Ipsos op-ed: Trump 2.0 represents a bold experiment in aligning governance with unfiltered public sentiment. A look at what history teaches us about this exercise and how that might define Trump’s second term.
-
How brands can ensure their influencers are influential
A surprising number of influencers inflate their follower counts, jeopardizing marketing campaigns and brand trust. Ipsos’ Eden Hazani explains how new tools can help brands verify and maximize the impact of their partnerships.
-
How Trump reshapes the world for brands
Nine global trends explain the ways the new administration will affect the way you do business
-
Insecurity in B2B Data Security
Take a look at insights from the Ipsos Business Insights Collective, exploring the perspectives of senior decision-makers on the evolving challenges of data privacy and security, and outlining the crucial steps organizations must take to fortify their defenses in the digital age.
-
Latest U.S. opinion polls archive
What are the data and trends shaping America today? Explore our latest opinion polls to learn more.
-
Improving access to healthcare by removing transportation barriers
Read how understanding the gaps and issues people face can give transportation planners, policymakers, and healthcare providers the data they need to tackle these problems in their communities.
-
Customer Perspective: An Ipsos Podcast
An Ipsos podcast series exploring best practices in customer experience strategies, mystery shopping and channel performance.
-
Ipsos Predictions Survey 2025: Positivity about how this year has gone highest since before the pandemic
The Ipsos Predictions Survey 2025 is a 33-country study which looks at people’s expectations and predictions for the year ahead.
-
[RECORDING] HIMSS: Innovations for more equitable obesity care
Ipsos’ Jackie Ilacqua joins a HIMSS panel discussion on the foresight to equitable obesity care and what's required within health system management to adapt successfully.
-
U.S. Biosimilars: Greater Access and New Commercial Models
Read more about the primary considerations that manufacturers – of both biosimilars and originator products – must factor into strategic plans going forward.